Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma, Inc. (NASDAQ: ATHA) revealed significant findings from its Phase 2 ACT-AD trial and new preclinical data during the AAN 2023 Annual Meeting. A post hoc analysis showed that patients treated with fosgonimeton exhibited a notable improvement in Mini-Mental State Examination (MMSE) scores (+1.6 pts, p=0.0350) and a decrease in neurodegeneration biomarkers. Additionally, preclinical data on ATH-1105 indicated prolonged survival and improved motor function in ALS mouse models. Athira continues to advance its exploration of the HGF/MET neurotrophic system as a potential treatment for neurodegenerative diseases, positioning ATHA for future clinical evaluation.

Athira Pharma, a biopharmaceutical company, announced upcoming presentations at the American Academy of Neurology (AAN) Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will feature new clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton for Alzheimer's disease, showcasing improvements in cognitive measures and plasma biomarkers. Additionally, preclinical research will support the therapeutic potential of fosgonimeton and ATH-1105 in neurodegenerative conditions, including ALS. The oral presentations will be led by Dr. Kevin Church and Dr. Hans J. Moebius on April 24 and 25, respectively. A poster presentation on ATH-1105's impact on motor function in an ALS model will occur on April 25. All presentations will be accessible on Athira's website post-event.

Athira Pharma (NASDAQ: ATHA) recently showcased preclinical data at the AD/PD 2023 conference, indicating that fosgonimeton may provide significant neuroprotective, neurotrophic, and anti-inflammatory benefits. Highlights include protection against neurite degeneration and cell death in neuronal cultures, reduced hyperphosphorylated tau levels, and decreased α-synuclein aggregation. The data suggests fosgonimeton could play a role in addressing Alzheimer’s and Parkinson’s diseases. Athira focuses on developing small molecules to restore neuronal health and progress its pipeline targeting the HGF/MET neurotrophic system.

Athira Pharma, Inc. (NASDAQ: ATHA) reported its financial results for the year ending December 31, 2022. The company is advancing its Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease, aiming for enrollment completion by mid-2023 and topline data in early 2024. Athira also progresses with ATH-1105 for ALS and maintains a robust balance sheet with $245.2 million in cash, down from $319.7 million in 2021. The net loss for 2022 was $95.6 million, or $2.53 per share, compared to a loss of $54.9 million, or $1.49 per share, in 2021. Increased operational costs were noted in R&D and G&A expenses.

Athira Pharma (NASDAQ: ATHA) is set to showcase its innovative small molecule therapeutics aimed at enhancing the HGF/MET system for treating various neurodegenerative diseases.

On March 15, 2023, Athira's management will participate in the Needham Neurosciences Investor Forum, followed by the Stifel 2023 CNS Days on March 28-29, 2023. Investors can access live webcasts of the presentations on Athira's website.

Focused on restoring neuronal health, Athira is advancing treatments for Alzheimer's and Parkinson's diseases, among others. The company emphasizes its commitment to developing effective therapies.

Athira Pharma, a late clinical-stage biopharmaceutical company, will present at two scientific conferences: ASENT 2023 from March 13-15 and AD/PD 2023 from March 28-April 1. The presentations will showcase preclinical data on enhancing the HGF/MET pathway for neurodegenerative diseases. Key presentations include oral and poster sessions focused on ATH-1105, ATH-1020, and Fosgonimeton, highlighting their neuroprotective properties in models of ALS, diabetic neuropathic pain, Alzheimer's, and Parkinson's diseases. These engagements aim to demonstrate the therapeutic potential of Athira's product candidates, emphasizing their innovative approach to restoring neuronal health.

Athira Pharma (NASDAQ: ATHA) recently released a review paper emphasizing the urgent need for innovative treatments for Alzheimer’s disease, specifically highlighting the potential of fosgonimeton, a small molecule modulator of the HGF/MET system. Published in the Journal of Alzheimer’s Disease, the article discusses current drug development limitations and the necessity for novel research methodologies. Athira's clinical candidate is currently being evaluated in the Phase 2/3 LIFT-AD study, targeting mild-to-moderate Alzheimer’s disease, with enrollment expected to conclude by mid-2023 and topline results anticipated in early 2024.

Athira Pharma, Inc. (NASDAQ: ATHA) has promoted Kevin Church, Ph.D., to Chief Scientific Officer, recognizing his vital role in advancing the company’s research on neurodegenerative diseases. Dr. Church, who has been with Athira since 2016, previously served as Executive Vice President of Research and has been instrumental in exploring the HGF/MET pathway for potential therapies targeting Alzheimer's, Parkinson's, and other neurological disorders. His leadership is expected to strengthen the company’s innovative approach to restoring neuronal health.

Athira Pharma (NASDAQ: ATHA) provided a pipeline update, highlighting its ongoing Phase 2/3 LIFT-AD study for mild-to-moderate Alzheimer’s disease with expected topline data in early 2024. The study aims to investigate the candidate fosgonimeton for neuroprotective effects. Additionally, ATH-1105, targeting amyotrophic lateral sclerosis (ALS), is set for an IND filing in 2023. Athira reported a solid financial position with $260 million in cash as of September 30, 2022, reinforcing its capability to advance its development programs.